Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 August 2019 | Story Charlene Stanley | Photo Stephen Collett
Prof Francis Petersen, Prof Puleng LenkaBula, William Bulwane and Min Thoko Didiza
Prof Francis Petersen, UFS Rector and Vice-Chancellor; Prof Puleng LenkaBula, Vice-Rector: Institutional Change, Student Affairs, and Community Engagement; Mr Kwekwe William Bulwane, Free State MEC for Agriculture and Rural Development; and Ms Thoko Didiza, Minister of Agriculture, Land Reform and Rural Development, who presented the 2019 Charlotte Maxeke public lecture.

“This work is not for yourselves. Kill that spirit of self. Do not live above your people. Live with them.” 
These famous words by Charlotte Maxeke, one of South Africa’s leading academic and social pioneers, formed the thrust of Minister Thoko Didiza's public lecture in a packed Equitas Auditorium on the UFS Bloemfontein Campus, three days before South Africans celebrate Woman’s Day.

The Agriculture, Land Reform and Rural Development Minister urged her audience to heed the “rich lessons this remarkable woman holds for our generation today”, in a lecture with the topic: Feminist Leadership, Intergenerational Dialogue on Knowledge, Agriculture and Sustainable Futures.

Educational pioneer

Referring to Maxeke’s many academic and cultural achievements, Minister Didiza pointed out that, “Her educational achievements did not make her see her fellow Africans any differently. It made her want to change their lives for the better.”
She called Maxeke a “true feminist, with an inclusive vision to fight for the betterment of all South Africans”.

This was echoed by Prof Francis Petersen, UFS Rector and Vice-Chancellor, in his welcoming address. He singled out the fact that Maxeke used to spend long hours tutoring her less skilled classmates while still at school.
“This wonderful example of using your own knowledge to make a real impact in the lives of others, is something we at the University of the Free State truly salute,” he said.  

Women’s conversation on land

On the topic of land reform, Minister Didiza referred to the fact that countries all over the world were involved in a ‘continuous process’ of land reform. She appealed to all South Africans to get involved in dialogues around the land issue.
“I know the pain and the cries of African people when it relates to land. But I don’t hear the cries and concerns of our white compatriots. Because until we understand each other’s pain, we will never be able to navigate the future.”
Minister Didiza then called for a ‘women’s conversation on land’, as she believed women to be ‘calmer’ than men and more inclined to collaborate with and listen to one another on an issue that is vital to all South African communities. 

Knowledge should lead to action

Minister Didiza said she believed universities had an important role to play in “gaining collective knowledge to solve problems”, and that agriculture should be a key focus area here – “benefitting from innovations in other sectors”.
“We need to urgently revitalise agriculture to once again bring glory to the Free State,” she said.
 “Knowledge means nothing if not translated into action and solutions for the problems we face in South Africa,” she concluded.

The Charlotte Maxeke lecture has been presented annually since 2009. Previous speakers include Minister Angie Motshekga, Prof Hlengiwe Mkhize and Dr Frene Ginwala.
 
Who was Charlotte Maxeke?

The CMM Institute describes her in this way:
“Charlotte Mannya-Maxeke (1871–1919) was a pioneering South African woman who was passionate about inclusivity, education and evangelism. She grasped every opportunity presented to her and accomplished many notable firsts during her lifetime.”
These ‘firsts’ include:
- being the first black woman in South Africa to obtain a BSc degree (at Wilberforce University in the United States of America in 1901);
- being the first woman to participate in the King’s Courts under King Sabata Dalindyebo of the AbaThembu;
- being the first African woman to establish a school (in Evaton, with her husband, in 1908);
- being the only woman who attended and contributed to the first African National Congress (ANC) conference in 1912; and
- being the co-initiator, organiser, and first President of the Bantu Women’s League, founded in 1918.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept